Latest News
News Functions
Additional Functions
9 July 2024
Immunic AG
Immunic Appoints Jason Tardio as Chief Operating Officer and President (news with additional features)
28 May 2024
Immunic AG
Immunic to Participate in Industry and Scientific Conferences in June
8 May 2024
Immunic AG
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
6 May 2024
Immunic AG
Immunic to Participate in Investor and Scientific Conferences in May
1 May 2024
Immunic AG
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
30 April 2024
Immunic AG
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in RRMS in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
4 April 2024
Immunic AG
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
20 March 2024
Immunic AG
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
7 March 2024
Immunic AG
Immunic to Participate in Investor and Scientific Conferences in March
29 February 2024
Immunic AG
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
22 February 2024
Immunic AG
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
15 February 2024
Immunic AG
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
1 February 2024
Immunic AG
Immunic to Participate in Investor and Scientific Conferences in February
5 January 2024
Immunic AG
Immunic Highlights 2023 Accomplishments and Upcoming Milestones
Immunic AG
Immunic, Inc. Announces Private Placement of up to $240 Million
21 November 2023
Immunic AG
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium’s Dosing Regimens in Multiple Sclerosis
2 November 2023
Immunic AG
Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts
26 October 2023
Immunic AG
Immunic to Participate in Scientific and Industry Conferences in November
16 October 2023
Immunic AG
Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023
15 October 2023
Immunic AG
Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023
11 October 2023
Immunic AG
Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting
9 October 2023
Immunic AG
Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
4 October 2023
Immunic AG
Immunic to Participate in Scientific Conferences in October
6 September 2023
Immunic AG
Immunic to Participate in Industry and Investor Conferences in September
17 August 2023
Immunic AG
Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
1 August 2023
Immunic AG
Immunic to Participate in Investor and Scientific Conferences in August
29 June 2023
Immunic AG
Immunic to Participate in Scientific and Investor Conferences in July
30 May 2023
Immunic AG
Immunic to Participate in Scientific and Investor Conferences in June
17 May 2023
Immunic AG
Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis
6 May 2023
Immunic AG
Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action